| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Bart De Strooper | Q4865062 |
| John Anthony Hardy | Q6237755 | ||
| Bengt Winblad | Q66000726 | ||
| Takaomi C Saido | Q88385095 | ||
| Shoko Hashimoto | Q88475584 | ||
| Kenichi Nagata | Q89236299 | ||
| Hiroki Sasaguri | Q90452901 | ||
| Per Nilsson | Q59558074 | ||
| Takashi Saito | Q42776201 | ||
| P2093 | author name string | Robert Vassar | |
| P2860 | cites work | Alzheimer's therapy targeting the β-secretase enzyme BACE1: Benefits and potential limitations from the perspective of animal model studies | Q38812007 |
| Genomics of Alzheimer Disease: A Review. | Q38822996 | ||
| Bisecting GlcNAc modification stabilizes BACE1 protein under oxidative stress conditions. | Q38827921 | ||
| Correlative Memory Deficits, Abeta Elevation, and Amyloid Plaques in Transgenic Mice | Q22242267 | ||
| TREM2 Variants in Alzheimer's Disease | Q22250873 | ||
| A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline | Q22251083 | ||
| Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein | Q22251280 | ||
| Alzheimer mechanisms and therapeutic strategies | Q22252311 | ||
| Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease | Q24312938 | ||
| Mutation of the mouse klotho gene leads to a syndrome resembling ageing | Q24328782 | ||
| Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model | Q24603560 | ||
| Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer's disease | Q24672501 | ||
| Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice | Q24681736 | ||
| Analysis of Amyloid Precursor Protein Function in Drosophila melanogaster | Q26738294 | ||
| The amyloid hypothesis of Alzheimer's disease at 25 years | Q26749528 | ||
| Genome Engineering with TALE and CRISPR Systems in Neuroscience | Q26752488 | ||
| Toward more predictive genetic mouse models of Alzheimer's disease | Q26771883 | ||
| The Amyloid Precursor Protein-A Novel Player within the Molecular Array of Presynaptic Nanomachines | Q26772807 | ||
| Clearance systems in the brain-implications for Alzheimer disease | Q26801541 | ||
| Self-propagation of pathogenic protein aggregates in neurodegenerative diseases | Q26996441 | ||
| The multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foes | Q27026919 | ||
| Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a "humanized" Abeta sequence | Q48915342 | ||
| Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. | Q48933018 | ||
| Single App knock-in mouse models of Alzheimer's disease. | Q50670713 | ||
| Loss of GPR3 reduces the amyloid plaque burden and improves memory in Alzheimer's disease mouse models | Q50702084 | ||
| AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease. | Q51371177 | ||
| Potential Link between Amyloid β-Protein 42 and C-terminal Fragment γ 49–99 of β-Amyloid Precursor Protein | Q51837859 | ||
| Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. | Q53203663 | ||
| Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice. | Q53219233 | ||
| Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. | Q53335187 | ||
| TREM2 and Neurodegenerative Disease | Q57418387 | ||
| Amyloid beta protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch) | Q57849311 | ||
| Ubiquitin-Dependent And Independent Signals In Selective Autophagy | Q38599451 | ||
| Induced pluripotent stem cells as a discovery tool for Alzheimer׳s disease | Q38605546 | ||
| Beyond γ-secretase activity: The multifunctional nature of presenilins in cell signalling pathways | Q38615871 | ||
| Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells | Q38666481 | ||
| The Cellular Phase of Alzheimer's Disease | Q38731102 | ||
| Defeating Alzheimer's disease and other dementias: a priority for European science and society | Q38778638 | ||
| Network abnormalities and interneuron dysfunction in Alzheimer disease | Q38796950 | ||
| Alzheimer's disease: experimental models and reality | Q39057135 | ||
| The discovery of Alzheimer-causing mutations in the APP gene and the formulation of the "amyloid cascade hypothesis". | Q39068135 | ||
| Unfolded protein response signaling by transcription factor XBP-1 regulates ADAM10 and is affected in Alzheimer's disease. | Q39069488 | ||
| Cognitive deficits in single App knock-in mouse models | Q39138139 | ||
| Targeting neoantigens to augment antitumour immunity | Q39149196 | ||
| Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. | Q39173722 | ||
| The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients | Q39222469 | ||
| Innate immunity in Alzheimer's disease: the relevance of animal models? | Q39314130 | ||
| Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice | Q39398322 | ||
| The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons | Q39884306 | ||
| Hypoxia Affects Neprilysin Expression Through Caspase Activation and an APP Intracellular Domain-dependent Mechanism. | Q40263247 | ||
| FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction | Q40737559 | ||
| Production of intracellular amyloid-containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence | Q40789635 | ||
| CCN1/CYR61 overexpression in hepatic stellate cells induces ER stress-related apoptosis | Q40930580 | ||
| Calpain Activation in Alzheimer's Model Mice Is an Artifact of APP and Presenilin Overexpression. | Q41138030 | ||
| Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein | Q41788034 | ||
| Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein | Q42491661 | ||
| A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity | Q43793656 | ||
| Aβ secretion and plaque formation depend on autophagy | Q44061458 | ||
| BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease | Q44722202 | ||
| Calpain mediates excitotoxic DNA fragmentation via mitochondrial pathways in adult brains: evidence from calpastatin mutant mice. | Q45251288 | ||
| Distinct mechanistic roles of calpain and caspase activation in neurodegeneration as revealed in mice overexpressing their specific inhibitors. | Q45256092 | ||
| The Swedish APP mutation alters the effect of genetically reduced BACE1 expression on the APP processing. | Q45901500 | ||
| Sodium channel cleavage is associated with aberrant neuronal activity and cognitive deficits in a mouse model of Alzheimer's disease. | Q45927250 | ||
| Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains. | Q46003834 | ||
| Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice | Q46143430 | ||
| Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. | Q46380915 | ||
| Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. | Q46384417 | ||
| Hallmarks of Alzheimer's Disease in Stem-Cell-Derived Human Neurons Transplanted into Mouse Brain | Q46412402 | ||
| Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation | Q46814179 | ||
| Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. | Q46959740 | ||
| Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis | Q48217048 | ||
| Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type | Q48265529 | ||
| Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice | Q48308608 | ||
| PLD3 gene and processing of APP. | Q48337321 | ||
| Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with A beta levels. | Q48373220 | ||
| Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. | Q48404445 | ||
| Brain/MINDS: A Japanese National Brain Project for Marmoset Neuroscience | Q48441682 | ||
| Lessons from a failed γ-secretase Alzheimer trial | Q48449453 | ||
| Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging | Q48463232 | ||
| Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins | Q48601563 | ||
| ScaleS: an optical clearing palette for biological imaging. | Q48651783 | ||
| Demonstration of Amyloid Deposits and Neurofibrillary Changes in Whole Brain Sections | Q48764154 | ||
| Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology | Q48773231 | ||
| Metabolic regulation of brain Abeta by neprilysin | Q48869458 | ||
| Rarity of the Alzheimer disease-protective APP A673T variant in the United States | Q27346292 | ||
| The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans | Q27697610 | ||
| The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease | Q28005463 | ||
| Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models | Q28119018 | ||
| A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain | Q28141707 | ||
| Comparison of the genomes of human and mouse lays the foundation of genome zoology | Q28185769 | ||
| Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease | Q28241772 | ||
| Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein | Q28260479 | ||
| Activity-dependent p25 generation regulates synaptic plasticity and Aβ-induced cognitive impairment | Q28590111 | ||
| The Evolution of Brains from Early Mammals to Humans | Q28709606 | ||
| Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction | Q29547778 | ||
| Decreased clearance of CNS beta-amyloid in Alzheimer's disease | Q29616534 | ||
| High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation | Q29616564 | ||
| Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model | Q29617937 | ||
| Clinical and biomarker changes in dominantly inherited Alzheimer's disease | Q29619940 | ||
| Genomic variants, genes, and pathways of Alzheimer's disease: An overview | Q30240093 | ||
| Alzheimer's disease | Q30251865 | ||
| Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model | Q30478167 | ||
| BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. | Q30483997 | ||
| Quantitative analysis of APP axonal transport in neurons: role of JIP1 in enhanced APP anterograde transport | Q30597672 | ||
| Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy | Q31031764 | ||
| Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation | Q32063777 | ||
| Alzheimer's disease: clinical trials and drug development | Q33349401 | ||
| Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP | Q33771562 | ||
| Endoplasmic reticulum stress mediates amyloid β neurotoxicity via mitochondrial cholesterol trafficking | Q33826820 | ||
| Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum | Q33870467 | ||
| BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time | Q33970104 | ||
| Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow | Q34042902 | ||
| Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo | Q34063772 | ||
| Probing the biology of Alzheimer's disease in mice | Q34206962 | ||
| Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production | Q34280406 | ||
| Brain endothelial cells produce amyloid {beta} from amyloid precursor protein 770 and preferentially secrete the O-glycosylated form | Q34401049 | ||
| Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models | Q34418781 | ||
| Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes | Q34452028 | ||
| The Alzheimer disease protective mutation A2T modulates kinetic and thermodynamic properties of amyloid-β (Aβ) aggregation | Q34467463 | ||
| National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease | Q34635272 | ||
| Mechanism of the cleavage specificity of Alzheimer's disease gamma-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein | Q35065215 | ||
| An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer's disease | Q35084401 | ||
| Systematic review of the relationship between amyloid-β levels and measures of transgenic mouse cognitive deficit in Alzheimer's disease | Q35137134 | ||
| Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies | Q35152946 | ||
| η-Secretase processing of APP inhibits neuronal activity in the hippocampus | Q35760228 | ||
| Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease. | Q35765178 | ||
| BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice | Q35809329 | ||
| The mechanism of γ-Secretase dysfunction in familial Alzheimer disease | Q36000134 | ||
| A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice | Q36027275 | ||
| Amyloid deposition and advanced age fails to induce Alzheimer's type progression in a double knock-in mouse model | Q36040886 | ||
| Pathophysiological roles of amyloidogenic carboxy-terminal fragments of the beta-amyloid precursor protein in Alzheimer's disease | Q36094025 | ||
| Neuronal Store-Operated Calcium Entry and Mushroom Spine Loss in Amyloid Precursor Protein Knock-In Mouse Model of Alzheimer's Disease. | Q36106832 | ||
| Rodent models for Alzheimer's disease drug discovery. | Q36117249 | ||
| Murine Aβ over-production produces diffuse and compact Alzheimer-type amyloid deposits | Q36278396 | ||
| Familial Alzheimer's disease mutations differentially alter amyloid β-protein oligomerization | Q36415249 | ||
| Transcriptional and translational regulation of BACE1 expression--implications for Alzheimer's disease | Q36564159 | ||
| Mutation in the 3'untranslated region of APP as a genetic determinant of cerebral amyloid angiopathy | Q36695844 | ||
| Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology | Q36724967 | ||
| Mobility and subcellular localization of endogenous, gene-edited Tau differs from that of over-expressed human wild-type and P301L mutant Tau | Q37064222 | ||
| Differential transgene expression patterns in Alzheimer mouse models revealed by novel human amyloid precursor protein-specific antibodies | Q37235627 | ||
| Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls | Q37259426 | ||
| BACE1 regulates voltage-gated sodium channels and neuronal activity | Q37355641 | ||
| Store-Operated Calcium Channel Complex in Postsynaptic Spines: A New Therapeutic Target for Alzheimer's Disease Treatment. | Q37445085 | ||
| Bidirectional Crosstalk between Lymphatic Endothelial Cell and T Cell and Its Implications in Tumor Immunity | Q37625551 | ||
| Differential contribution of APP metabolites to early cognitive deficits in a TgCRND8 mouse model of Alzheimer's disease | Q37665855 | ||
| 'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? | Q37764575 | ||
| Cerebral cortical development in rodents and primates | Q37974428 | ||
| Cognitive components in mice and humans: combining genetics and touchscreens for medical translation | Q38116667 | ||
| Amyloid precursor protein and neural development | Q38222924 | ||
| Alzheimer's disease genetics: from the bench to the clinic | Q38225911 | ||
| A molecular web: endoplasmic reticulum stress, inflammation, and oxidative stress. | Q38239644 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 17 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| protein precursor | Q258658 | ||
| membrane protein | Q423042 | ||
| animal disease model | Q64732998 | ||
| biomedical investigative technique | Q66648976 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 2473-2487 | |
| P577 | publication date | 2017-08-01 | |
| 2017-09-01 | |||
| P1433 | published in | The EMBO Journal | Q1278554 |
| P1476 | title | APP mouse models for Alzheimer's disease preclinical studies | |
| P478 | volume | 36 |
| Q64101612 | A Cautionary Tale: Endogenous Biotinylated Proteins and Exogenously-Introduced Protein A Cause Antibody-Independent Artefacts in Western Blot Studies of Brain-Derived Proteins |
| Q90732117 | A Human Embryonic Stem Cell Model of Aβ-Dependent Chronic Progressive Neurodegeneration |
| Q64265088 | Aberrant Excitatory-Inhibitory Synaptic Mechanisms in Entorhinal Cortex Microcircuits During the Pathogenesis of Alzheimer's Disease |
| Q61811401 | Age-related Disturbances in DNA (hydroxy)methylation in APP/PS1 Mice |
| Q91045286 | Ageing and amyloidosis underlie the molecular and pathological alterations of tau in a mouse model of familial Alzheimer's disease |
| Q93248642 | All (animal) models (of neurodegeneration) are wrong. Are they also useful? |
| Q64088896 | Alzheimer Aβ Assemblies Accumulate in Excitatory Neurons upon Proteasome Inhibition and Kill Nearby NAKα3 Neurons by Secretion |
| Q91877796 | Amyloid Beta and Tau Cooperate to Cause Reversible Behavioral and Transcriptional Deficits in a Model of Alzheimer's Disease |
| Q61811494 | Amyloid β perturbs elevated heme flux induced with neuronal development |
| Q64068921 | Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer's disease |
| Q91526804 | Amyloid-β-independent regulators of tau pathology in Alzheimer disease |
| Q93018574 | An impaired intrinsic microglial clock system induces neuroinflammatory alterations in the early stage of amyloid precursor protein knock-in mouse brain |
| Q57143848 | Animal models of neurodegenerative diseases |
| Q64068852 | ApoE4: an emerging therapeutic target for Alzheimer's disease |
| Q90697479 | Astaxanthin Ameliorated Parvalbumin-Positive Neuron Deficits and Alzheimer's Disease-Related Pathological Progression in the Hippocampus of AppNL-G-F/NL-G-F Mice |
| Q96129239 | Biophysical studies of protein misfolding and aggregation in in vivo models of Alzheimer's and Parkinson's diseases |
| Q90929220 | Brain organoids: a next step for humanized Alzheimer's disease models? |
| Q90396209 | Can mouse models mimic sporadic Alzheimer's disease? |
| Q42371397 | Caspase-8, association with Alzheimer's Disease and functional analysis of rare variants |
| Q64110888 | Cell Type-Specific Human APP Transgene Expression by Hippocampal Interneurons in the Tg2576 Mouse Model of Alzheimer's Disease |
| Q100307290 | Cerebrospinal fluid sTREM2 in Alzheimer's disease: comparisons between clinical presentation and AT classification |
| Q57040842 | Chronic oral application of a periodontal pathogen results in brain inflammation, neurodegeneration and amyloid beta production in wild type mice |
| Q90587999 | Cognitive and emotional alterations in App knock-in mouse models of Aβ amyloidosis |
| Q92501586 | Contribution of GABAergic interneurons to amyloid-β plaque pathology in an APP knock-in mouse model |
| Q53397508 | Critical review: involvement of endoplasmic reticulum stress in the aetiology of Alzheimer's disease. |
| Q91410950 | Dementia in Down syndrome: unique insights for Alzheimer disease research |
| Q57471358 | ER stress is not elevated in the 5XFAD mouse model of Alzheimer's disease |
| Q92187874 | Early Cognitive and Behavioral Deficits in Mouse Models for Tauopathy and Alzheimer's Disease |
| Q64946332 | Early-Onset Molecular Derangements in the Olfactory Bulb of Tg2576 Mice: Novel Insights Into the Stress-Responsive Olfactory Kinase Dynamics in Alzheimer's Disease. |
| Q47234302 | Endoplasmic reticulum stress responses in mouse models of Alzheimer disease: overexpression paradigm versus knock-in paradigm |
| Q48043354 | Exceptional in vivo catabolism of neurodegeneration-related aggregates |
| Q64067761 | Experimental Pharmacology in Transgenic Rodent Models of Alzheimer's Disease |
| Q92964504 | Exploring the efficacy of natural products in alleviating Alzheimer's disease |
| Q92572573 | Factors other than hTau overexpression that contribute to tauopathy-like phenotype in rTg4510 mice |
| Q50039492 | Gamma oscillations in the entorhinal-hippocampal circuit underlying memory and dementia. |
| Q47332864 | Gasotransmitter hydrogen sulfide signaling in neuronal health and disease |
| Q54965183 | Generation of App knock-in mice reveals deletion mutations protective against Alzheimer's disease-like pathology. |
| Q60935279 | Genomics: New Light on Alzheimer's Disease Research |
| Q57160792 | Herpes simplex virus-1 specifically targets human CD1d antigen presentation to enhance its pathogenicity |
| Q61444197 | Heterochromatic genome instability and neurodegeneration sharing similarities with Alzheimer's disease in old Bmi1+/- mice |
| Q58761831 | Human Alzheimer's disease gene expression signatures and immune profile in APP mouse models: a discrete transcriptomic view of Aβ plaque pathology |
| Q90754253 | Imbalance in the response of pre- and post-synaptic components to amyloidopathy |
| Q93158341 | Immune Signaling in Neurodegeneration |
| Q55365163 | Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model. |
| Q93000628 | Intracellular Calcium Dysregulation by the Alzheimer's Disease-Linked Protein Presenilin 2 |
| Q52310735 | Lack of human-like extracellular sortilin neuropathology in transgenic Alzheimer's disease model mice and macaques. |
| Q96952556 | Leveraging preclinical models for the development of Alzheimer disease therapeutics |
| Q90390163 | M1 muscarinic receptor is a key target of neuroprotection, neuroregeneration and memory recovery by i-Extract from Withania somnifera |
| Q90206387 | Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities |
| Q55073016 | Microglia in Alzheimer's Disease: Activated, Dysfunctional or Degenerative. |
| Q92483746 | Modeling Alzheimer's disease with iPSC-derived brain cells |
| Q59549217 | Modeling Alzheimer’s disease brains in vitro |
| Q92000754 | Modeling and Targeting Alzheimer's Disease With Organoids |
| Q90295696 | Mouse models of Alzheimer's disease cause rarefaction of pial collaterals and increased severity of ischemic stroke |
| Q91199030 | Neural oscillations during cognitive processes in an App knock-in mouse model of Alzheimer's disease pathology |
| Q90359231 | Neurodegenerative diseases: model organisms, pathology and autophagy |
| Q64933464 | Neuroinflammation in mouse models of Alzheimer's disease. |
| Q93379781 | Neuroinflammatory Cytokines Induce Amyloid Beta Neurotoxicity through Modulating Amyloid Precursor Protein Levels/Metabolism |
| Q91404770 | New Alzheimer's disease model mouse specialized for analyzing the function and toxicity of intraneuronal Amyloid β oligomers |
| Q50072580 | Noncoding RNAs in Alzheimer's disease |
| Q58787421 | Novel Quantitative Analyses of Spontaneous Synaptic Events in Cortical Pyramidal Cells Reveal Subtle Parvalbumin-Expressing Interneuron Dysfunction in a Knock-In Mouse Model of Alzheimer's Disease |
| Q90162258 | Overview of Transgenic Mouse Models for Alzheimer's Disease |
| Q64279068 | Partial Identification of Amyloid-β Degrading Activity in Human Serum |
| Q98163701 | Phosphorylated Aβ peptides in human Down syndrome brain and different Alzheimer's-like mouse models |
| Q47135235 | Practical considerations for choosing a mouse model of Alzheimer's disease |
| Q91890979 | Preclinical Models of Alzheimer's Disease: Relevance and Translational Validity |
| Q52721951 | Prion-like propagation of β-amyloid aggregates in the absence of APP overexpression. |
| Q58800414 | Protein Co-Aggregation Related to Amyloids: Methods of Investigation, Diversity, and Classification |
| Q60926571 | Proteolytic cleavage of Beclin 1 exacerbates neurodegeneration |
| Q57800439 | Questions concerning the role of amyloid-β in the definition, aetiology and diagnosis of Alzheimer's disease |
| Q89174583 | Reagent Validation to Facilitate Experimental Reproducibility |
| Q58027500 | Rodent models for Alzheimer disease |
| Q50288922 | Role of Copper in the Onset of Alzheimer's Disease Compared to Other Metals. |
| Q55365674 | Sex Differences in Healthspan Predict Lifespan in the 3xTg-AD Mouse Model of Alzheimer's Disease. |
| Q89501868 | Sleep and EEG Power Spectral Analysis in Three Transgenic Mouse Models of Alzheimer's Disease: APP/PS1, 3xTgAD, and Tg2576 |
| Q93134029 | Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer's disease progression |
| Q89253294 | Spontaneous development of Alzheimer's disease-associated brain pathology in a Shugoshin-1 mouse cohesinopathy model |
| Q46257963 | Studies for Improving a Rat Model of Alzheimer's Disease: Icv Administration of Well-Characterized β-Amyloid 1-42 Oligomers Induce Dysfunction in Spatial Memory. |
| Q92501860 | Tau binding protein CAPON induces tau aggregation and neurodegeneration |
| Q91797951 | Tau- but not Aß -pathology enhances NMDAR-dependent depotentiation in AD-mouse models |
| Q92055304 | Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice |
| Q54977832 | The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. |
| Q59806753 | The Emerging Role of Altered Cerebellar Synaptic Processing in Alzheimer's Disease |
| Q90275177 | The Major Risk Factors for Alzheimer's Disease: Age, Sex, and Genes Modulate the Microglia Response to Aβ Plaques |
| Q88947004 | The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes |
| Q89980820 | The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease |
| Q49823902 | The mitochondrial transcription factor TFAM in neurodegeneration: emerging evidence and mechanisms |
| Q88427169 | The role of adult hippocampal neurogenesis in brain health and disease |
| Q64109478 | Ultrastructural evidence of microglial heterogeneity in Alzheimer's disease amyloid pathology |
| Q55019485 | Using Drosophila Models of Amyloid Toxicity to Study Autophagy in the Pathogenesis of Alzheimer's Disease. |
| Q57471412 | Whole brain imaging reveals distinct spatial patterns of amyloid beta deposition in three mouse models of Alzheimer's disease |
Search more.